Polar’s Titan Test: Week 1 Ignites Hope in a Crypto-Fueled Cancer Fight

Polar Inu’s cosmic arc blazes with defiance. Our 10-year-old husky, Polar, is locked in a battle with anal sac adenocarcinoma (ASAC)—a rare, aggressive cancer that’s just 1% of canine tumors. We first noticed swelling in May 2024 and, fearing a tumor, switched to a ketogenic diet in June as an interim shield. Diagnosis hit in June 2024: ASAC, with a vet prognosis of 6-18 months untreated. Polar’s defied 10 so far. A $500 Ethereum-funded consult with Dr. William Makis launched a 12-week protocol on March 30, 2025—and week 1’s results stun: inflammation’s crashed, tumors are easing. Could this spark a crypto-first cancer triumph?

Enter Dr. Makis: The Titan Slayer
Dr. William Makis, a Canadian physician with expertise in radiology, oncology, and nuclear medicine, has authored over 100 peer-reviewed papers and thrives on defying odds. On X (@MakisMD) and Substack (substack.com/@makismd), he champions repurposed drugs—ivermectin, fenbendazole, Vitamin C—claiming remission in Stage 4 giants:

Stage 4 Colon Cancer: Metastatic remission, against ~14% 5-year survival.

Stage 4 Breast Cancer: Tumor shrinkage, topping ~22%.

Stage 4 Lung Cancer (NSCLC): Success beyond ~7%.

Stage 4 Pancreatic Cancer: Rare wins, defying ~3%.

Glioblastoma: Outliving ~5% survival.

Lymphomas: Beating 30-40% late-stage rates.

His strategy? Starve tumors of glucose via keto (per Dr. Thomas Seyfried) and hit them with tailored drug combos. X posts highlight rapid turnarounds—like a prostate PSA dropping from 141 to 0.25 in 3 months—or preclinical data on ivermectin’s anti-cancer bite. It’s bold and anecdotal, but Makis consistently doubles or triples survival odds in dire cases.

Polar’s Battle: Week 1 Brings a Striking Turn
Polar’s ASAC is brutal: 20-30% 5-year survival with surgery, 12-24 months if metastatic. We started keto in June 2024, pre-diagnosis, and added Seyfried’s press-pulse therapy (metabolic stress) by mid-November, holding Polar at 10 months against a grim clock. But swelling lingered—until Makis’s consult. His protocol, started March 30, includes:

Keto with Press-Pulse: Since June and mid-November, adjusted to Makis’s plan.

Confidential Vet Paste: Daily, per Makis.

Ivermectin Paste: Twice daily, topical,

Oral Ivermectin: Added post-MDR1 clearance (March 29).

Five days in (March 30-April 3), the anal sac area—swollen for months—has transformed. Inflammation’s plummeted across the board, and the tumors seem caught in the tide: less turgid, less pronounced, their blood volume depleted, not as split or menacing.

After months of stubborn inflammation, this 5-day crash is a jolt, hinting at more than surface-level change.
The Odds: 40-50%—Does Inflammation’s Drop Boost It?

Vets peg Polar’s odds at 30-40% with surgery and chemo—20-30% for 5 years, lower if metastatic.

Makis, surgery-free, projects 40-50%—maybe more—for tumor reduction by June 29, 2025.

His baseline? A 20-30% Stage 4 remission rate (e.g., pancreatic from 3% to 20%), week 1’s shift, and ASAC’s fit with his tough-cancer wins.

But does this inflammation drop alone nudge the odds higher? Here’s how:
Inflammation as a Tumor Ally: Chronic swelling often fuels tumors—ASAC included—via cytokines (e.g., IL-6) that drive growth and angiogenesis (blood supply). Makis’s X-cited studies (e.g., ivermectin’s anti-inflammatory effects) suggest quashing it starves tumors indirectly. Polar’s anal sac inflammation crashing in 5 days—after months—points to ivermectin’s rapid kick, likely hitting tumor-driven swelling too.

Tumor Volume Clue: The tumors’ “easing”—less blood-heavy, less pronounced—ties to reduced inflammation. We can’t isolate tumor shrinkage from general anal sac relief yet, but their depleted look suggests a metabolic or vascular hit. Makis’s X anecdotes (e.g., lung tumors shrinking 70% in a month) show early inflammation drops as precursors to remission—boosting odds beyond vet baselines.

Odds Impact: If inflammation alone drives 5-10% of Makis’s 40-50% (e.g., stabilizing Polar), its sudden collapse could add another 5-10% edge—pushing “maybe more” toward 50-55%. Even conservatively, it’s a signal: tumors aren’t immune to the area’s downturn, aligning with his 20-30% Stage 4 uplift.

It’s early—week 1 isn’t victory—but this isn’t just edema fading. The anal sac-tumor link and ivermectin’s dual action (anti-inflammatory, anti-cancer) make this a pivotal boost to Makis’s projection.
A Crypto Vision Unfolds

Polar’s fight tests Makis’s titan-slaying grit and a crypto dream. Polar Inu’s $5K market cap could soar—$500K, $1M, echoing our $1.3M past—if remission lands by June. Tracked at x.com/PolarInu_SOL, this blends oncology with Solana’s pulse. Makis’s 500,000+ X followers could rocket this story, pioneering a crypto-funded cancer model.

Polar’s defying the odds—Makis’s vision and our interim shield turned cosmic. Join us on this star-chasing ride.

Disclaimer: Not vet advice; consult experts.